NASDAQ:INVO INVO Bioscience (INVO) Stock Price, News & Analysis $0.75 -0.01 (-1.32%) (As of 12/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About INVO Bioscience Stock (NASDAQ:INVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get INVO Bioscience alerts:Sign Up Key Stats Today's Range$0.74▼$0.7850-Day Range$0.73▼$1.2452-Week Range$0.63▼$3.50Volume39,601 shsAverage Volume1.59 million shsMarket Capitalization$2.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewINVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.Read More… Receive INVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address INVO Stock News HeadlinesINVO Bioscience (NASDAQ:INVO) Trading Down 3.9% - Here's WhyDecember 12, 2024 | americanbankingnews.comNAYA Biosciences to present insights into mode of action of NY-303November 1, 2024 | markets.businessinsider.comThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… December 22, 2024 | Crypto 101 Media (Ad)NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular CarcinomaOctober 24, 2024 | globenewswire.comNAYA Biosciences Inc (INVO)October 24, 2024 | investing.comINVO Bioscience confirms name change, new trading symbol following NAYA mergerOctober 22, 2024 | markets.businessinsider.comINVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA BiosciencesOctober 21, 2024 | globenewswire.comUnited States shares higher at close of trade; Dow Jones Industrial Average up 0.47%October 14, 2024 | msn.comSee More Headlines INVO Stock Analysis - Frequently Asked Questions How have INVO shares performed this year? INVO Bioscience's stock was trading at $1.35 at the start of the year. Since then, INVO shares have decreased by 44.4% and is now trading at $0.75. View the best growth stocks for 2024 here. How were INVO Bioscience's earnings last quarter? INVO Bioscience, Inc. (NASDAQ:INVO) posted its earnings results on Monday, November, 15th. The company reported ($4.80) EPS for the quarter, missing the consensus estimate of ($4.00) by $0.80. The firm earned $0.22 million during the quarter, compared to analysts' expectations of $0.25 million. When did INVO Bioscience's stock split? Shares of INVO Bioscience reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are INVO Bioscience's major shareholders? INVO Bioscience's top institutional investors include CWC Advisors LLC. (2.64%). Insiders that own company stock include Andrea Goren, Steve Shum, Michael Jos Campbell and Matthew K Szot. View institutional ownership trends. How do I buy shares of INVO Bioscience? Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of INVO Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI). Company Calendar Last Earnings11/15/2021Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:INVO CUSIPN/A CIK1417926 Webwww.invobioscience.com Phone(978) 878-9505FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,030,000.00 Net Margins-122.79% Pretax Margin-122.32% Return on EquityN/A Return on Assets-36.94% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.27 Sales & Book Value Annual Sales$5.77 million Price / Sales0.50 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.36Miscellaneous Outstanding Shares3,809,000Free Float3,769,000Market Cap$2.86 million OptionableNo Data Beta1.43 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:INVO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.